6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00605553 (ClinicalTrials.gov)	April 2008	15/1/2008	Study to Evaluate SYN115 in Parkinson's Disease	A Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Study to Explore the Effects of 7 Days of Dosing With SYN115 20 mg p.o. BID or 60 mg p.o. BID on Clinical and fMRI Response to Intravenous Levodopa in Patients With Mild to Moderate Parkinson's Disease	Parkinson's Disease	Drug: Placebo;Drug: Tozadenant	Biotie Therapies Inc.	NULL	Completed	40 Years	75 Years	All	30	Phase 2	United States
2	NCT00089622 (ClinicalTrials.gov)	August 4, 2004	6/8/2004	Lisuride Patch to Treat Parkinson's Disease	Transcutaneous Lisuride Therapy of Parkinson's Disease	Parkinson Disease	Drug: Intravenous Levodopa;Drug: Lisuride Transdermal System	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	40 Years	80 Years	All	40	Phase 2	United States
3	NCT00086294 (ClinicalTrials.gov)	June 25, 2004	29/6/2004	ACP-103 to Treat Parkinson's Disease	5HT2A/C Serotonin Blockade in Parkinson's Disease	Parkinson's Disease;Dyskinesias	Drug: Intravenous Levodopa;Drug: ACP-103	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	30 Years	80 Years	All	40	Phase 2	United States
4	NCT00076674 (ClinicalTrials.gov)	January 2004	28/1/2004	Levetiracetam Treatment of L-dopa Induced Dyskinesias	Levetiracetam Treatment of L-dopa Induced Dyskinesias	Dyskinesias;Parkinson Disease	Drug: Intravenous Levodopa	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	40	Phase 2	United States